Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Positive Metastatic Breast Cancers”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT04872166
What this trial is testing

BTX-A51 in People With Advanced Solid Tumor and Breast Cancer

Who this might be right for
Advanced Solid TumorMetastatic Breast Cancer
Edgewood Oncology Inc. 112
Testing effectiveness (Phase 2)WithdrawnNCT07570966
What this trial is testing

Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Who this might be right for
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsMetastatic Castration-resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)UnknownNCT04407988
What this trial is testing

Pyrotinib in Combination With Letrozole in Patients With HER2-Positive, ER-Positive Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Hunan Cancer Hospital 86
Not applicableStudy completedNCT04517305
What this trial is testing

Pyrotinib Plus Vinorelbine in HER2+ Metastatic Breast Cancer Patients

Who this might be right for
Breast Cancer
Fudan University 97
Testing effectiveness (Phase 2)Ended earlyNCT00377780
What this trial is testing

Liposomal Doxorubicin, Trastuzumab, and Docetaxel in HER2 Positive Metastatic Breast Cancer

Who this might be right for
Breast CancerNeoplasm Metastasis
Laurence J.C. van Warmerdam 60
Testing effectiveness (Phase 2)Study completedNCT02536794
What this trial is testing

MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer

Who this might be right for
Estrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu Negative+2 more
Northwestern University 30
Early research (Phase 1)Looking for participantsNCT06503783
What this trial is testing

BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors

Who this might be right for
Breast CancerSolid Tumor
Sichuan Baili Pharmaceutical Co., Ltd. 20
Not applicableStudy completedNCT07416409
What this trial is testing

Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer

Who this might be right for
Breast NeoplasmsOncologyHER2-positive Breast Cancer+1 more
Deraya University 80
Early research (Phase 1)Study completedNCT04382352
What this trial is testing

B002 in Patients With HER2-positive Breast Cancer

Who this might be right for
Recurrent Breast CancerMetastatic Breast Cancer
Shanghai Pharmaceuticals Holding Co., Ltd 23
Testing effectiveness (Phase 2)Ended earlyNCT04738292
What this trial is testing

Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)

Who this might be right for
ER-positive Breast CancerHER2-negative Breast CancerMetastatic Cancer
University of Wisconsin, Madison 11
Early research (Phase 1)WithdrawnNCT03846583
What this trial is testing

Tucatinib + Abemaciclib + Herceptin for HER2+ MBC

Who this might be right for
Breast Cancer
Dana-Farber Cancer Institute
Testing effectiveness (Phase 2)Study completedNCT00191451
What this trial is testing

Gemcitabine and Carboplatin (Plus Herceptin in Human Epidermal Growth Factor Receptor 2 Positive [HER2+] Patients) With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Eli Lilly and Company 150
Large-scale testing (Phase 3)Study completedNCT00320385
What this trial is testing

Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer

Who this might be right for
Neoplasms, Breast
GlaxoSmithKline 296
Early research (Phase 1)Study completedNCT00849329
What this trial is testing

Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer

Who this might be right for
Neoplasms, Breast
GlaxoSmithKline 12
Testing effectiveness (Phase 2)Study completedNCT04307329
What this trial is testing

Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trial

Who this might be right for
Breast Cancer
The Netherlands Cancer Institute 12
Testing effectiveness (Phase 2)Study completedNCT03222856
What this trial is testing

Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & Taxanes

Who this might be right for
Breast Cancer
MedSIR 44
Testing effectiveness (Phase 2)Ended earlyNCT01477060
What this trial is testing

Modulation of Response to Hormonal Therapy With Lapatinib and/or Metformin in Patients With Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Fondazione Michelangelo 32
Testing effectiveness (Phase 2)UnknownNCT04088110
What this trial is testing

Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer

Who this might be right for
Breast Cancer FemaleHER2-positive Breast CancerHormone Receptor Positive Malignant Neoplasm of Breast+3 more
Fuzhou General Hospital 77
Early research (Phase 1)Study completedNCT02060253
What this trial is testing

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

Who this might be right for
HER2-positive Breast CancerMale Breast CancerRecurrent Breast Cancer+4 more
Memorial Sloan Kettering Cancer Center 9
Post-approval studies (Phase 4)Study completedNCT02445586
What this trial is testing

Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 52
Next Page